Oppenheimer & CO Inc Viking Therapeutics, Inc. Transaction History
Oppenheimer & CO Inc
- $6.43 Billion
- Q1 2025
A detailed history of Oppenheimer & CO Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 144,543 shares of VKTX stock, worth $4.14 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
144,543
Previous 121,062
19.4%
Holding current value
$4.14 Million
Previous $4.87 Million
28.35%
% of portfolio
0.05%
Previous 0.07%
Shares
8 transactions
Others Institutions Holding VKTX
# of Institutions
451Shares Held
64.9MCall Options Held
5.8MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$291 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$172 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$141 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.2 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.7 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.19B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...